{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '2', 'Table of Contents', '1', 'STUDY SYNOPSIS', '2', '2', 'TABLE OF CONTENTS', '10', '3', 'CONTACTS', '13', '4', 'SIGNATURE PAGE', '15', '5', 'LIST OF ABBREVIATIONS AND DEFINITION OF TERMS', '17', '6', 'INTRODUCTION', '21', '6.1', 'Background and Rationale', '21', '6.2', 'Potential Risks and Benefits', '23', '7', 'STUDY OBJECTIVES AND PURPOSE', '24', '7.1', 'Primary Objective', '24', '7.2', 'Secondary Objective(s)', '24', '8', 'STUDY DESIGN', '25', '8.1', 'Description of the Study Design', '25', '8.2', 'Study Endpoints', '25', '8.2.1 Primary Endpoint(s)', '25', '8.2.2 Secondary Endpoint(s)', '25', '8.2.3 Exploratory Endpoints', '26', '8.3', 'Patient Identification', '26', '8.4', 'Withdrawal of Patients', '26', '8.5', 'Discontinuation of Entire Study', '27', '9', 'SELECTION OF PATIENTS', '29', '9.1', 'Inclusion / Exclusion Criteria', '29', '9.1.1 Inclusion Criteria', '29', '9.1.2 Exclusion Criteria', '30', '10 STUDY MEDICATION', '32', '10.1 Investigational and Control Drugs', '32', '10.2 Route of Administration, Dosage, Dosage Regimen and Treatment Period', '32', '10.3 Packaging and Labelling', '33', '10.4 Storage of Study Medication', '33', '10.5 Study Medication Supply and Re-supply, Accountability Procedures', '33', '10.6 Instructions for Supplying and Taking the Study Medication', '34', '10.6.1 Treatment after End of Study', '34', '10.7 Permitted Study Medication Dose Adjustments and Interruptions', '34', '10.8 Prior and Concomitant Treatment', '35', '10.8.1 Permitted Treatments', '35', '10.8.2 Prohibited Treatments', '35', '10.9 Procedures for Monitoring Compliance', '35', '11 STUDY SCHEDULE', '37', '11.1 Study Flow Chart', '37', '11.2 Study Visit Description', '37', 'Page 10 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '11.2.1 Visit 1 - (Screening / Day -28 - 1)', '37', '11.2.2', 'Visit 2 - (Baseline / Day 0)', '37', '11.2.3', 'Visit 3 - (Week 4, Day 28 +4)', '38', '11.2.4 Visit 4 - (Week 12, Day 84 4)', '38', '11.2.5', 'Visit 5 - (Week 20, Day 140 +7)', '39', '11.2.6', 'Early Termination Visit', '39', '11.2.7', 'Unscheduled Visits', '40', '12 ASSESSMENTS', '41', '12.1 Efficacy Assessments', '41', '12.1.1 Dermatology Life Quality Index (DLQI)', '41', '12.1.2', 'Psoriasis Area and Severity Index (PASI)', '41', '12.1.3', 'Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) 41', '12.1.4', \"Physician's Global Assessment (PGA)\", '41', \"12.1.5 Dynamic Hand and Feet (H&F) Physician's Global Assessment\", '42', '12.1.6', \"Hand and Feet (H&F) Physician's Global Assessment\", '42', '12.1.7', 'Pustules Count', '42', '12.1.8', 'Visual Analogue Scale (VAS)', '42', '12.1.9', 'Photo Documentation', '42', '12.1.10', 'Exploratory assessments', '43', '12.2 Safety Assessments', '44', '12.2.1', 'Adverse Events (AE)', '44', '12.2.2', 'Pregnancy Test', '44', '12.2.3 Physical Examination and Vital Signs', '44', '12.3 Demographics and Baseline Characteristics', '45', '12.3.1', 'Patient Demography', '45', '12.3.2', 'Medical History', '45', '12.3.3', 'Psoriasis History', '45', '12.3.4', 'Nicotine Anamnesis', '46', '13 ADVERSE EVENT REPORTING', '47', '13.1 Definitions', '47', '13.2 Record of Adverse Events', '48', '13.3 Procedures for Reporting Serious Adverse Events', '49', '13.4 Pregnancy', '50', '14 STATISTICS', '51', '14.1 Protocol Deviations', '51', '14.2 Analysis Populations', '51', '14.3 Demographics and Baseline Characteristics', '52', '14.4 Treatments', '52', '14.5 Analysis of Primary Endpoint', '52', '14.5.1 Primary Endpoint', '52', '14.5.2', 'Statistical Methods of Analysis', '52', '14.6 Analysis of Secondary Efficacy Endpoints', '53', '14.7 Analysis of Secondary Safety Endpoints', '53', '14.8 Exploratory Analysis', '53', '14.9 Handling of Missing Values', '54', 'Page 11 of 75']\n\n###\n\n", "completion": "END"}